Advanced Chemical Industries Limited

1st Quarter ended Report 2022-2023 for the three months period ended on 30 September 2022

Advanced Chemical Industries Limited

Statement of financial position Unaudited

		Fi	igures in '000' Taka	
8		As at	As at	
	Note	30 September 2022	30 June 2022	
Assets				
Property, plant and equipment	2	13,653,948	13,472,344	
Right-of-use assets	-	686,238	392,249	
Investments	3	3,241,794	3,267,746	
Intangible assets		1,727	1,943	
Biological assets		34,334	31,303	
Deferred tax assets		89,097	47,611	
Non-current assets		17,707,138	17,213,196	
Inventories	4	8,077,251	7,187,025	
Trade receivables	5	2,766,903	2,768,624	
Other receivables	U	823,863	608,506	
Inter-company receivables	6	27,754,040	26,285,592	
Advances, deposits and prepayments	7	750,012	855,536	
Cash and cash equivalents	,	1,452,331	794,546	
Current assets		41,624,401	38,499,829	
Total assets		59,331,538	55,713,025	
Equity				
Share capital		725,768	725,768	
Share premium		402,310	402,310	
Reserves		5,090,107	5,114,365	
Retained earnings		14,633,449	14,426,635	
Total equity		20,851,635	20,669,079	
Liabilities				
Employee benefits	8	1,288,996	1,210,620	
Long term borrowings	9	1,084,836	1,068,990	
Non-current portion of lease liabilities		493,741	305,310	
Non-current liabilities		2,867,573	2,584,920	
Bank overdraft		4,185,096	3,357,929	
Loans and borrowings	10	23,243,864	20,344,561	
Current portion of lease liabilities		148,906	116,945	
Trade payables		1,239,511	1,325,615	
Inter-company payables	11	3,185,872	3,999,74	
Other payables	12	3,130,050	2,834,922	
Unclaimed/unpaid dividend account		82,155	82,81	
Current tax liabilities		396,876	396,490	
Current liabilities		35,612,331	32,459,020	
Total liabilities		38,479,904	35,043,940	
Total equity and liabilities		59,331,538	55,713,025	

Net asset value (NAV) per share (in Taka)

Lehm

/Lompany Secretary

287.30

Managing Director

Director

Chief Financial Officer

284.79

Advanced Chemical Industries Limited Statement of profit or loss Unaudited

с. С		Figures in '000' Ta				
	- Note	For the 1st Quarter ended from				
		July 2022 to September 2022	July 2021 to September 2021			
Revenue	13	6,842,780	7,638,988			
Cost of sales	14	(3,955,573)	(4,224,412)			
Gross profit		2,887,206	3,414,577			
Administrative, selling and distribution expenses	15	(2,528,047)	(2,419,458)			
Other income		101,486	29,245			
Operating profit		460,646	1,024,363			
Net finance costs		(113,976)	(94,010)			
Profit before contribution to WPPF		346,670	930,353			
Contribution to WPPF		(17,333)	(46,518)			
Profit before tax		329,336	883,836			
Income tax expense		(122,523)	(239,137)			
Profit after tax		206,814	644,699			

Earnings per share

Basic and diluted earnings per share (EPS) (in Taka)

Managing Director

Director

Chief Financial Officer

dompany Secretary

8.88

2.85

		igures in '000' Taka arter ended from
Other comprehensive income: Change in fair value of FVOCI financial asset	July 2022 to September 2022	July 2021 to September 2021
Profit after tax	206,814	644,699
Other comprehensive income:		
Change in fair value of FVOCI financial assets	(26,953)	(24,503)
Income tax on FVOCI financial assets	2,695	2,450
Other comprehensive income, net of tax	(24,258)	(22,053)
Total comprehensive income	182,556	622,647

Advanced Chemical Industries Limited Statement of profit or loss and other comprehensive income Unaudited

Advanced Chemical Industries Limited Statement of changes in equity Unaudited

						Figures i	n '000' Taka
			For th	e period up to 1	st Quarter from .	July 2022 to Sep	tember 2022
	Share capital	Share premium	Capital reserve	FVOCI reserve	Revaluation surplus	Retained earnings	Total equity
Balance at 1 July 2022	725,768	402,310	1,671	401,449	4,711,245	14,426,635	20,669,079
Total comprehensive income							
Profit after tax	-	-	-	-	-	206,814	206,814
Other comprehensive income-net of tax	-	-	-	(24,258)	-	-	(24,258)
Total comprehensive income	-	-	-	(24,258)	-	206,814	182,556
Transaction with owners of the Company							
Share premium	-	-	-	-	-	-	-
Stock dividend	-	-	-	-	-	-	-
Cash dividend	-	-	-	-	-	-	-
Total transactions with owners of the Company	-	-	-	-	-	-	
Balance at 30 September 2022	725,768	402,310	1,671	377,191	4,711,245	14,633,449	20,851,635

	For the period up to 1st Quarter from July 2021 to Se							
	Share capital	Share premium	Capital reserve	FVOCI reserve	Revaluation surplus	Retained earnings	Total equity	
Balance at 1 July 2021	631,103	402,310	1,671	453,052	4,711,245	12,693,655	18,893,035	
Total comprehensive income								
Profit after tax	-	-	-	-	-	644,699	644,699	
Other comprehensive income-net of tax	-	-	-	(22,053)	-	-	(22,053)	
Total comprehensive income	-	-	-	(22,053)	-	644,699	622,647	
Transaction with owners of the Company								
Share premium	-	-	-	-	-	-	-	
Stock dividend	-	-	-	-	-	-	-	
Cash dividend	-	-	-	-	-	-	-	
Total transactions with owners of the Company	-	-	-	-	-	-	-	
Balance at 30 September 2021	631,103	402,310	1,671	430,999	4,711,245	13,338,354	19,515,682	

Advanced Chemical Industries Limited Statement of cash flows

Unaudited	

		F	igures in '000' Taka
		For the 1st Qua	arter ended from
		July 2022	July 2021
		to	to
		September 2022	September 2021
Cash flows from operating activities			
Cash receipts from customers and others		6,680,258	7,610,489
Cash paid to suppliers and employees		(6,913,062)	(6,179,595)
Cash generated from / (used in) operating activities		(232,804)	1,430,894
Paid to WPPF		(6,343)	(8,311)
Finance costs paid		(103,602)	(83,344)
Income tax paid		(160,927)	(167,410)
		(270,872)	(259,065)
Net cash from / (used in) operating activities*	16	(503,676)	1,171,829
Cash flows from investing activities			
Acquisition of property, plant and equipment		(81,301)	(37,131)
Payments for capital work in progress		(219,643)	(202,345)
Sale proceeds from property, plant and equipment		45	-
Purchase of biological assets		(4,020)	(781)
Investment		(1,000)	-
Net cash from / (used in) investing activities		(305,919)	(240,257)
Cash flows from financing activities			
Inter-company debts received/(paid)		(2,235,096)	(3,905,395)
Dividend paid		(661)	(42,330)
Payment for lease liabilities		(40,298)	
			(45,232)
Short-term bank loan received/(paid)		2,890,866	981,545
Long-term bank loan received/(paid)		24,283	(32,525)
Net cash from / (used in) financing activities		639,094	(3,043,937)
Net increase / (decrease) in cash and cash equivalents		(170,499)	(2,112,364)
Opening cash and cash equivalents		(2,563,383)	(9,153)
Effect of movements in exchange rates on cash held		1,117	-
Closing cash and cash equivalents		(2,732,765)	(2,121,517)
Closing balance represents			
Cash and cash equivalents		1,452,331	1,373,522
Bank overdraft		(4,185,096)	(3,495,040)
		(2,732,765)	(2,121,517)
Net operating cash flows per share (NOCFPS) (in Tak	`	(6.94)	16.15

*See Note 16 for reconciliation of net operating cash flow.

Advanced Chemical Industries Limited Consolidated statement of financial position Unaudited

	Unaudited			
		As at	gures in '000' Taka As at	
	Note	As at 30 September 2022	As at 30 June 2022	
	11010	50 September 2022	50 June 2022	
Assets				
Property, plant and equipment	2 (a)	30,986,978	30,439,75	
Right-of-use assets	2220 (1997) 23	2,214,057	1,720,12	
Equity-accounted investees		2,200,130	2,157,94	
Other investments		917,918	822,29	
Intangible assets		77,518	82,29	
Biological assets		34,334	31,30	
Deferred tax assets		838,055	709,842	
Non-current assets		37,268,990	35,963,55.	
Inventories	4 (a)	24,318,510	20,323,250	
Trade receivables	5 (a)	14,651,035	12,772,253	
Other receivables		1,083,732	832,50	
Inter-company receivables	6 (a)	5,671	5,61	
Advances, deposits and prepayments	7 (a)	3,257,790	2,512,49	
Current tax assets		145,270	103,392	
Cash and cash equivalents		2,972,543	3,208,75	
Current assets		46,434,551	39,758,264	
Total assets		83,703,541	75,721,817	
Equity				
Share capital		725,768	725,768	
Share premium		1,231,094	1,231,094	
Reserves		6,918,366	6,950,48	
Retained earnings		1,111,571	1,397,370	
Equity attributable to the owners of the Company		9,986,799		
Non-controlling interest			10,304,725	
Total equity		1,994,529	1,899,967	
		11,981,327	12,204,692	
Liabilities Employee benefits	8 (a)	1,683,407	1,583,157	
Long term borrowings	9 (a)			
Non-current portion of lease liabilities	9 (a)	6,634,052 1,717,057	6,408,915	
Non-current liabilities		10,034,516	1,384,718 9,376,790	
ton-current natinities		10,034,510	9,570,790	
Bank overdraft		6,286,105	, 5,177,120	
Loans and borrowings	10 (a)	41,420,975	35,271,595	
Current portion of lease liabilities		403,381	382,47	
Trade payables		6,256,297	5,518,32	
Other payables	12 (a)	7,233,525	7,702,734	
Unclaimed/unpaid dividend account		87,415	88,082	
Current liabilities		61,687,698	54,140,334	
Fotal liabilities		71,722,214	63,517,125	
Total equity and liabilities		83,703,541	75,721,817	
Net asset value (NAV) per share (in Taka)	18	137.60	141.98	
Λ		107100		

J. Jahmer Director

Managing Director

Chief Financial Officer

. /

Company Secretary

6

		'000' Taka				
		For the 1st Quarter ended from				
	Note	July 2022 to September 2022	July 2021 to September 2021			
Revenue	13 (a)	26,784,046	21,553,672			
Cost of sales	13 (a) 14 (a)	(20,669,824)	(15,624,213)			
Gross profit		6,114,223	5,929,460			
Administrative, selling and distribution expenses	15 (a)	(4,875,046)	(4,297,570)			
Other income		197,150	75,275			
Operating profit	X	1,436,326	1,707,165			
Share of the profit of equity accounted investees		42,186	79,944			
Net finance costs		(1,177,515)	(884,541)			
Profit before contribution to WPPF		300,998	902,568			
Contribution to WPPF		(63,290)	(83,583)			
Profit before tax		237,708	818,984			
Income tax expense		(423,692)	(517,699)			
Profit after tax		(185,984)	301,285			
Profit attributable to:						
Equity holders of the company		(285,806)	248,153			
Non-controlling interests		99,821	53,132			
Profit after tax		(185,984)	301,285			
Earnings per share						
Basic and diluted earnings per share (EPS) (in Taka)	18	(3.94)	3.42			

Advanced Chemical Industries Limited Consolidated statement of profit or loss Unaudited

Managing Director

Director

Chief Financial Officer

Company Secretary

	Figures in '0 For the 1st Quar	00' Taka ter ended from
	July 2022 to September 2022	July 2021 to September 2021
Profit after tax	(185,984)	301,285
Other comprehensive income:		
Foreign operations - foreign currency translation differences	(13,203)	(4,803)
Change in fair value of FVOCI financial assets	(27,975)	(23,709)
Income tax on other comprehensive income	2,798	2,371
Other comprehensive income, net of tax	(38,381)	(26,141)
Total comprehensive income	(224,365)	275,144
Total comprehensive income attributable to:		
Equity holders of the Company		
Profit after tax	(285,806)	248,153
Other comprehensive income	(32,121) (317,927)	(25,959) 222,195
Non-controlling interest		
Profit after tax	99,821	53,132
Other comprehensive income	(6,259)	(182)
	93,562	52,949
Total comprehensive income	(224,365)	275,144

Advanced Chemical Industries Limited Consolidated statement of profit or loss and other comprehensive income Unaudited

Advanced Chemical Industries Limited Consolidated Statement of changes in equity Unaudited

Figures in '000' Taka

For the period up to 1st Quarter from July 2022 to September 2022

		Attributable to owners of the Company								
	Share capital	Share premium	Capital reserve	Translation reserve	FVOCI reserve	Revaluation reserve	Retained earnings	Total	Non-controlling Interests	Total equity
Balance at 1 July 2022	725,768	1,231,094	1,671	(80,757)	399,525	6,630,048	1,397,376	10,304,725	1,899,967	12,204,692
Total comprehensive income										
Profit after tax	-	-	-	-	-	-	(285,806)	(285,806)	99,821	(185,984)
Other comprehensive income-net of tax	-		-	(7,367)	(24,754)	-	-	(32,121)	(6,259)	(38,381)
Total comprehensive income	-	-	-	(7,367)	(24,754)	-	(285,806)	(317,927)	93,562	(224,365)
Transaction with owners of the Company										
Share premium	-	-	-	-	-	-	-	-	-	-
Stock dividend	-	-	-	-	-	-	-	-	-	-
Cash dividend	-	-	-	-	-	-	-	-	-	-
Capital contribution by non-controlling interest	-	-	-	-	-	-	-	-	1,000	1,000
Total transactions with owners of the Company	-	-	-	-	-	-	-	-	1,000	1,000
Balance at 30 September 2022	725,768	1,231,094	1,671	(88,124)	374,770	6,630,048	1,111,571	9,986,799	1,994,529	11,981,327

For the period up to 1st Quarter from July 2021 to September 2021

			Α	ttributable to o	wners of the (Company				
	Share capital	Share premium	Capital reserve	Translation reserve	FVOCI reserve	Revaluation surplus	Retained earnings	Total	Non-controlling Interests	Total equity
Balance at 1 July 2021	631,103	928,707	1,671	(1,397)	452,007	6,632,367	1,620,385	10,264,844	838,207	11,103,051
Total comprehensive income										
Profit after tax	-	-	-	-	-	-	248,153	248,153	53,132	301,285
Other comprehensive income-net of tax	-		-	(4,464)	(21,495)	-	-	(25,959)	(182)	(26,141)
Total comprehensive income	-	-	-	(4,464)	(21,495)	-	248,153	222,195	52,949	275,144
Transaction with owners of the Company										
Share premium	-	-	-	-	-	-	-	-	-	-
Stock dividend	-	-	-	-	-	-	-	-	-	-
Cash dividend	-	-	-	-	-	-	-	-	-	
Total transactions with owners of the Company	-	-	-	-	-	-	-	-	-	-
Balance at 30 September 2021	631,103	928,707	1,671	(5,860)	430,512	6,632,367	1,868,538	10,487,038	891,157	11,378,195

Advanced Chemical Industries Limited Consolidated statement of cash flows Unaudited

Cash flows from operating activities Cash receipts from customers and others Cash paid to suppliers and employees Cash generated from / (used in) operating activities	For the 1st Qu July 2022 to	uarter ended from July 2021
Cash receipts from customers and others Cash paid to suppliers and employees	•	July 2021
Cash receipts from customers and others Cash paid to suppliers and employees	to	JULY 2021
Cash receipts from customers and others Cash paid to suppliers and employees		to
Cash receipts from customers and others Cash paid to suppliers and employees	September 2022	September 2021
Cash receipts from customers and others Cash paid to suppliers and employees		
Cash paid to suppliers and employees		
	24,119,155	21,576,165
Cash generated from / (used in) operating activities	(28,957,030)	(21,513,972)
	(4,837,875)	62,192
Paid to WPPF	(13,744)	(11,209)
Finance costs paid	(786,478)	(727,889)
Income tax paid	(563,491)	(470,280)
	(1,363,713)	(1,209,377)
Net cash from / (used in) operating activities * 16 (a)	(6,201,589)	(1,147,185)
Cash flows from investing activities		
Acquisition of property, plant and equipment	(139,462)	(59,898)
Payments for capital work in progress	(799,467)	(232,570)
Sale proceeds from property, plant and equipment	2,045	-
Purchase of biological assets	(4,020)	(781)
Short term investments	-	(14,335)
Long term investments	(122,600)	(12,997)
Net cash from / (used in) investing activities	(1,063,504)	(320,581)
Cash flows from financing activities		
Inter-company debts received/(paid)	(58)	110
Dividend paid	(661)	(42,330)
Payment for lease liabilities	(106,160)	(123,568)
Dividend paid to non-controlling interest	(6)	(8,086)
Short-term bank loan received/(paid)	4,622,189	791,381
Long-term bank loan received/(paid)	1,398,669	(856,880)
Net cash from / (used in) financing activities	5,913,974	(239,373)
Net increase / (decrease) in cash and cash equivalents	(1,351,119)	(1,707,140)
Opening cash and cash equivalents	(1,968,368)	287,985
Effect of movements in exchange rates on cash held	5,926	343
Closing cash and cash equivalents	(3,313,562)	(1,418,812)
Closing balance represents		
Cash and cash equivalents	2,972,543	4,091,679
Bank overdraft	(6,286,105)	(5,510,491)
	(3,313,562)	(1,418,812)
Net operating cash flows per share (NOCFPS) (in Taka) 18	(85.45)	(15.81)

*See Note 16(a) for reconciliation of consolidated net operating cash flow.

1 Selected explanatory notes

These financial statements have been prepared in line with Accounting Policies as adopted in the preparation of financial statements for the year ended from 1 July 2021 to 30 June 2022. This interim financial report includes only those selected explanatory notes as deemed appropriate for better understanding of unaudited financial statements.

		Fig	ures in '000' Taka		
2	Property, plant and equipment	30 September 2022	30 June 2022		
		Taka	Taka		
	Opening balance	16,402,682	15,407,109		
	Additions and revaluation	300,944	1,009,436		
	Disposals and adjustments	(1,242)	(13,863)		
	Accumulated depreciation	(3,048,436)	(2,930,338)		
	Closing balance	13,653,948	13,472,344		
2 (a)	Consolidated property, plant and equipment				
	Opening balance	39,082,739	36,940,749		
	Additions and revaluation	938,783	2,179,879		
	Disposals and adjustments	(1,242)	(33,362)		
	Accumulated depreciation	(9,033,303)	(8,647,514)		
	Closing balance	30,986,978	30,439,752		
3	Investments				
	Investment in subsidiaries	1,751,736	1,751,736		
	Investment in joint ventures	510,000	510,000		
	Investment in associates	681,563	681,563		
	Investment in shares	501,557	527,510		
	Investment in FDR/ other deposits	70,538	70,538		
	Impairment	(273,600)	(273,600)		
		3,241,794	3,267,746		
4	Inventories				
	Raw materials	3,182,339	2,805,504		
	Packing materials	655,045	641,063		
	Work-in-process	421,469	384,174		
	Finished goods	3,700,706	3,269,607		
	Goods in transit	705,968	612,094		
	Stores and spares	101,810	93,268		
	Allowance for inventory	(690,086)	(618,685)		
		8,077,251	7,187,025		

		Fig 30 September 2022 Taka	ures in '000' Taka 30 June 2022 Taka
4 (a)	Raw materials Packing materials Work-in-process Finished goods Goods in transit Stores & spares Allowance for inventory Trade receivables Debts due over six months Debts due below six months Provision for doubtful debts		
	Raw materials	7,840,287	6,819,248
	Packing materials	743,307	733,206
	-	808,030	783,525
	•	13,542,595	11,022,482
	÷	2,051,396	1,478,350
	Stores & spares	416,795	376,143
	-	(1,083,900)	(889,706)
		24,318,510	20,323,250
5	Trade receivables		
	Debts due over six months	1,893,706	1,885,401
	Debts due below six months	1,615,850	1,586,756
	Provision for doubtful debts	(742,653)	(703,533)
		2,766,903	2,768,624
5 (a)	Consolidated trade receivables		
	Debts due over six months	4,374,410	4,174,836
	Debts due below six months	11,786,960	10,056,732
	Provision for doubtful debts	(1,510,335)	(1,459,314)
		14,651,035	12,772,253
6	Inter-company receivables		
	ACI Logistics Limited	8,311,668	8,602,694
	ACI HealthCare Limited	7,955,935	7,022,751
	ACI Foods Limited	4,073,635	3,699,602
	Premiaflex Plastics Limited	3,543,006	3,484,408
	ACI Agrolink Limited	1,002,457	932,792
	ACI Biotech Limited	994,763	963,401
	ACI HealthCare USA Inc.	796,292	727,796
	Infolytx Bangladesh Limited	639,718	610,649
	ACI Chemicals Limited	237,142	232,071
	ACI Edible Oils Limited	189,936	-
	Asian Consumer Care (Pvt.) Limited	7,894	7,894
	ACI Godrej Agrovet (Pvt.) Limited	930	930
	Tetley ACI (Bangladesh) Limited	633	575
	Computer Technology Limited	30	30
		27,754,040	26,285,592

		Fig 30 September 2022 Taka	ures in '000' Taka 30 June 2022 Taka	
6 (a)	Consolidated inter-company receivables			
	Computer Technology Limited	30	30	
	Tetley ACI (Bangladesh) Limited	633	575	
	Asian Consumer Care (Pvt.) Limited	7,894	7,894	
	ACI Godrej Agrovet (Pvt.) Limited	930	930	
	Stochastic Logic Limited	(3,816)	(3,816)	
		5,671	5,613	
7	Advances, deposits & prepayments			
	Advances to staff, suppliers and others	185,124	241,100	
	VAT current account	162,551	197,537	
	Deposits	234,564	271,812	
	Prepayments	167,773	145,087	
		750,012	855,536	
7 (a)	Consolidated advances, deposits & prepayments			
	Advances to staff, suppliers and others	1,814,661	1,219,522	
	VAT current account	529,466	439,695	
	Deposits	492,418	523,608	
	Prepayments	421,245	329,673	
		3,257,790	2,512,498	
8	Employee benefits			
	Staff gratuity provision	1,011,444	950,030	
	Other long term employee benefits	277,552	260,590	
		1,288,996	1,210,620	
8 (a)	Consolidated employee benefits			
	Staff gratuity provision	1,313,812	1,232,845	
	Other long term employee benefits	369,595	350,312	
		1,683,407	1,583,157	

		Fig 30 September 2022 Taka	Figures in '000' Taka 30 June 2022 Taka	
9	Long term borrowings			
	Long term bank loans	1,084,836	1,068,990	
		1,084,836	1,068,990	
9 (a)	Consolidated long term borrowings			
	Long term bank loans	6,634,052	6,408,915	
		6,634,052	6,408,915	
10	Loans and borrowings - short term			
	Short term loan	23,003,711	20,112,845	
	Current portion of long term loan	240,153	231,717	
		23,243,864	20,344,561	
10 (a)	Consolidated loans and borrowings - short term			
	Short term loan	38,970,869	33,242,131	
	Current portion of long term loan	2,450,106	2,029,464	
		41,420,975	35,271,595	
11	Inter company payables			
	ACI Marine and Riverine Technologies Limited	43,810	42,455	
	ACI Motors Limited	569,933	934,628	
	ACI Salt Limited	1,643,938	1,616,152	
	ACI Pure Flour Limited	389,223	490,029	
	ACI Edible Oils Limited	-	64,330	
	Creative Communication Limited	61,321	62,811	
	ACI Formulations Limited	473,831	785,527	
	Stochastic Logic Limited	3,816	3,816	
		3,185,872	3,999,748	

		Fig 30 September 2022 Taka	ures in '000' Taka 30 June 2022 Taka
12	Other payables		
	Accruals	1,532,186	1,307,201
	Advance from customers	40,036	23,915
	Security money received from customers	35,932	35,848
	Workers' profit participation fund	822,768	800,536
	Tax and VAT deducted at source	138,365	99,752
	Employees welfare fund	415,351	415,177
	Rights share deposit to be refunded	564	564
	Family day fund	6,069	5,880
	Non-management staff provident fund	7,018	6,021
	Unclaimed refund warrant - Zero Coupon Bonds	3,647	3,647
	Payable for redemption of Zero Coupon Bonds	20,403	20,403
	Management staff provident fund	17,109	26,599
	Advertisement and promotional funds	80,430	78,244
	Development funds	10,171	11,134
	<u>.</u>	3,130,050	2,834,922
12 (a)	Consolidated other payables		
	Accruals	4,699,548	4,338,038
	Advance from customers	338,051	1,321,581
	Security money received from customers	100,570	98,065
	Workers' profit participation fund	1,208,633	1,141,424
	Management staff provident fund	17,109	26,599
	Tax and VAT deducted at source	321,514	235,630
	Employees welfare fund	415,351	415,177
	Rights share deposit to be refunded	564	564
	Family day fund	6,069	5,880
	Non-management staff provident fund	7,018	6,021
	Unclaimed refund warrant - Zero Coupon Bonds	3,647	3,647
	Payable for redemption of Zero Coupon Bonds	20,403	20,403
	Creditors for capital expenditure	350	326
	Advertisement and promotional funds	80,430	78,244
	Development funds	14,266	11,134
•		7,233,525	7,702,734

		Figures in '00				
			arter ended from			
		July 2022	July 2021			
		to	to			
		September 2022	September 2021			
13	Revenue	Taka	Taka			
15	Kevenue					
	Pharmaceuticals	3,258,041	4,038,388			
	Animal health	1,138,353	1,089,856			
	Consumer brands	1,723,250	1,709,955			
	Seeds	293,842	272,993			
	Fertilizer	337,270	466,004			
	Animal genetics	92,023	61,792			
		6,842,780	7,638,988			
13 (a)	Consolidated revenue					
	Gross sales	27,534,509	22,043,034			
	Inter-company sales	(750,462)	(489,362)			
	Inter-company sales	26,784,046	21,553,672			
14	Cost of sales					
	Opening stock	7,100,348	6,685,551			
	Purchase	4,170,959	3,768,085			
		11,271,307	10,453,636			
	Closing stock	(7,959,559)	(6,872,203)			
		3,311,748	3,581,433			
	Manufacturing expenses	643,825	642,979			
		3,955,573	4,224,412			
14 (a)	Consolidated cost of sales					
	Opening stock	19,364,928	16,031,441			
	Purchase	22,983,485	16,233,542			
	1 urenuse	42,348,413	32,264,983			
	Closing stock	(22,940,684)	(17,902,626)			
	Closing stock	19,407,729	14,362,357			
	Manufacturing expenses	1,262,095	1,261,855			
	Manufacturing expenses	20,669,824	15,624,213			
15	Administrative, selling and distribution expenses					
	Administrative expenses	150,664	151,641			
	-	308,205	289,396			
	Distribution expenses					
	Selling expenses	2,069,179	1,978,421			
		2,528,047	2,419,458			

		Fig For the 1st Quarte	gures in '000' Taka er ended from
	_	July 2022 to September 2022 Taka	July 2021 to September 2021 Taka
15 (a)	Consolidated operating expenses		
	Administrative expenses Distribution expenses Selling expenses	633,246 705,658 3,536,142 4,875,046	554,731 594,995 3,147,843 4,297,570
16	Reconciliation of net operating cash flow		
	Profit after tax Adjustment for non-cash items and others:	206,814	644,699
	 -Unrealized gain on translation of foreign currency receivable Depreciation and amoritisation Provisions Finance cost Tax Expense Contribution to WPPF -Lease and other adjustments 	(47,228) 119,441 110,521 113,976 122,523 17,333 41,104	117,795 155,312 94,010 239,137 46,518 44,629
	Changes in:		
	 Inventories Trade and other receivables Advances, deposits and prepayments Trade and other payables, employment benefits 	(961,627) (252,757) 33,045 264,051	(232,557) (172,600) 160,013 333,939
	Cash generated from operating activities	(232,804)	1,430,894
	Paid to WPPF Interest paid Income tax paid Net cash from operating activities	(6,343) (103,602) (160,927) (503,676)	(8,311) (83,344) (167,410) 1,171,829
16 (a)	Reconciliation of Consolidated net operating cash flow		
	Profit after tax	(185,984)	301,285
	 Adjustment for non-cash items and others: Depreciation and amoritisation Provisions Share of profit of equity accounted investees Finance cost Tax Expense Contribution to WPPF Lease and other adjustments 	396,233 245,215 (42,186) 1,177,515 423,692 63,290 106,220	380,531 126,873 (79,944) 884,541 517,699 83,583 123,568

Changes in:		
- Inventories	(4,189,454)	(1,505,002)
- Trade and other receivables	(2,181,034)	(154,355)
- Advances, deposits and prepayments	(819,782)	215,414
- Trade and other payables, Employment benefits	168,401	(832,002)
Net cash from operating activities	(4,837,875)	62,192
Paid to WPPF	(13,744)	(11,209)
Interest paid	(786,478)	(727,889)
Income tax paid	(563,491)	(470,280)
Net cash from operating activities	(6,201,589)	(1,147,185)

17 Consolidated operating segments Please see Annexure A.

18

	•	gures in '000' Taka
	For the 1st Quarter	uly 2021
	to	to
	September 2022	September 2021
Consolidated EPS, NAV per share, and NOCFPS		
Weighted average number of ordinary shares (in thousand)	72,577	72,577
Consolidated profit attributable to equity		
holders of the Company (Taka '000)	(285,806)	248,153
Earnings per share (Taka)	(3.94)	3.42
Consolidated cash flows from operating activities		
(Taka '000)	(6,201,589)	(1,147,185)
Net operating cash flows per share (NOCFPS)	(85.45)	(15.81)
	30 September 2022	30 June 2022
	Taka	Taka
Consolidated net asset attributable to equity		
holders of the Company (Taka '000)	9,986,799	10,304,725
Net asset value (NAV) per share	137.60	141.98

Reasons for significant deviations: During the three months period ended on 30 September 2022, the Group achieved a significant revenue growth which was mainly contributed by the sales growth in some of the business segments as demonstrated in Annexure-A: Consolidated operating segments. However, the substantial increase in costs due to macroeconomic factors, including significant uprise of import costs caused by devaluation of local currency against US Dollar, led to the decline in consolidated profit compared to the SPLY. The consequential results of decreased consolidated profit ultimately led to decrease in consolidated EPS. On the other hand, NOCFPS decreased mainly due to investment in working capital to facilitate business growth in coming months.

19 Figures have been rounded off to the nearest '000' Taka and previous period's figures have been rearranged to conform to current period's presentation.

Annexure-A

Consolidated operating segments

Figures in '000' Taka For the period up to 1st Quarter from July 2022 to September 2022

	Reportable Segment											Total	Unallocated/	
Particulars	Pharmaceuticals	Animal Health	Consumer Brands	Crop Care and Public Health	Motors	Pure Flour	Retail Chain	Salt	Foods	Premiaflex	HealthCare	reportable segments	Elimination	Total
External revenue	3,258,041	1,138,353	1,665,287	1,065,191	6,065,603	2,238,622	3,979,633	738,352	2,512,071	1,716,674	626,436	25,004,263	1,779,783	26,784,046
Inter-segment revenue	-	-	169,580	-	49,709	43,742	14,994	22,311	83,520	236,116	69,476	689,448	61,014	750,462
Segment revenue	3,258,041	1,138,353	1,834,867	1,065,191	6,115,312	2,282,364	3,994,627	760,663	2,595,591	1,952,790	695,913	25,693,711	1,840,797	27,534,509
Depreciation and amortisation	76,583	6,047	23,856	4,704	20,701	9,699	34,827	19,947	16,692	67,912	90,694	371,661	24,572	396,233
Operating expenses	1,770,859	244,033	421,853	159,028	666,253	103,809	728,469	70,988	174,528	146,491	154,754	4,641,065	233,982	4,875,046
Finance cost / (income)	80,870	44,400	48,559	27,995	96,667	(7,264)	349,646	(23,323)	91,379	130,986	350,503	1,190,418	(12,903)	1,177,515
Segment profit/(loss) before tax	88,733	77,293	(65,918)	125,656	521,473	41,945	(315,057)	132,298	42,538	30,201	(614,736)	64,426	173,282	237,708
Segment assets at 30 Sep 2022	13,084,674	2,589,623	4,922,160	3,566,519	16,120,848	2,326,395	4,716,187	3,446,764	3,723,644	7,655,673	9,367,669	71,520,157	12,183,384	83,703,541
Segment liabilities at 30 Sep 2022	4,296,621	1,541,412	2,035,184	2,026,698	7,621,346	1,032,527	19,796,981	1,320,502	5,488,455	7,184,312	15,709,543	68,053,581	3,668,633	71,722,214

For the period up to 1st Quarter from July 2021 to September 2021

	Reportable segment											Total	Unallocated/	
Particulars	Pharmaceuticals	Animal Health	Consumer Brands	Crop Care and Public Health	Motors	Pure Flour	Retail Chain	Salt	Foods	Premiaflex	HealthCare	reportable segments	Elimination	Total
External revenue	4,038,388	1,089,856	1,623,150	815,853	3,751,162	1,338,767	2,999,101	698,347	1,860,373	1,470,396	419,077	20,104,470	1,449,202	21,553,672
Inter-segment revenue	-	-	208,043	-	9,657	17,286	21,601	21,468	28,157	146,241	-	452,452	36,910	489,362
Segment revenue	4,038,388	1,089,856	1,831,193	815,853	3,760,819	1,356,053	3,020,702	719,814	1,888,530	1,616,636	419,077	20,556,921	1,486,113	22,043,034
Depreciation and amortisation	74,455	6,530	22,524	4,744	18,855	9,534	40,747	15,485	16,306	67,075	87,925	364,182	16,349	380,531
Operating expenses	1,564,509	228,395	533,872	145,388	504,155	68,362	612,275	74,919	163,812	126,211	79,826	4,101,723	195,846	4,297,570
Finance cost / (income)	32,970	19,040	18,530	25,749	50,343	(10,731)	306,996	(20,739)	70,258	116,202	218,587	827,205	57,337	884,541
Segment profit/(loss) before tax	774,757	68,874	(68,144)	98,818	458,639	(9,288)	(303,277)	132,339	44,945	(47,666)	(438,939)	711,060	107,924	818,984
Segment assets at 30 June 2022	12,573,985	2,146,396	4,716,029	2,541,478	14,137,726	2,113,795	4,413,875	3,298,908	3,510,890	7,791,047	8,304,796	65,548,925	10,172,892	75,721,817
Segment liabilities at 30 June 2022	2,875,165	807,677	2,192,264	1,216,550	6,001,189	843,534	19,153,460	1,261,464	5,303,295	7,305,712	13,991,888	60,952,199	2,564,926	63,517,125